Literature DB >> 13729933

[The degradation products of human fibrinogen by plasmin. II. Immunological study: existence of native anti-fibrinogen antibodies possessing different specificities].

V NUSSENZWEIG, M SELIGMANN, P GRABAR.   

Abstract

Entities:  

Keywords:  FIBRINOLYSIS

Mesh:

Substances:

Year:  1961        PMID: 13729933

Source DB:  PubMed          Journal:  Ann Inst Pasteur (Paris)        ISSN: 0020-2444


× No keyword cloud information.
  12 in total

1.  [The mechanism of blood cell sedimentation. XVIII. Sedimentation effect of fibrinogen plasminolysis products].

Authors:  H Hörmann
Journal:  Blut       Date:  1975-01

2.  INVESTIGATION OF A QUANTITATIVE ANOMALY ENCOUNTERED IN THE ASSAY OF FIBRINOGEN BY IMMUNO-DIFFUSION.

Authors:  P WOLF; K W WALTON
Journal:  Immunology       Date:  1965-01       Impact factor: 7.397

3.  [FETAL FIBRINOGEN. IV. STUDIES ON THE IMMUNOLOGICAL AND PHYSICO-CHEMICAL BEHAVIOR OF FETAL FIBRINOGEN].

Authors:  U STORB; P CORVAZIER; W KUENZER
Journal:  Klin Wochenschr       Date:  1965-05-01

4.  Pathogenesis of the coagulation defect developing during pathological plasma proteolytic ("fibrinolytic") states. II. The significance, mechanism and consequences of defective fibrin polymerization.

Authors:  N ALKJAERSIG; A P FLETCHER; S SHERRY
Journal:  J Clin Invest       Date:  1962-04       Impact factor: 14.808

5.  [The serum protein picture in obstetrical afibrinogenemia. Dysproteinemia as a consequence of uncoagulable fibrinogen derivatives].

Authors:  D F Steichele; H J Herschlein; I Woerner
Journal:  Klin Wochenschr       Date:  1966-03-01

6.  The detection of fibrinogen-fibrin degradation products by means of a new antibody-coated latex particle.

Authors:  M B Garvey; J M Black
Journal:  J Clin Pathol       Date:  1972-08       Impact factor: 3.411

7.  Assay of serum fibrin degradation products by agglutination-inhibition of coated erythrocytes.

Authors:  P C Das
Journal:  J Clin Pathol       Date:  1970-05       Impact factor: 3.411

8.  Acute promyelocytic leukemia with hypofibrinogenemia.

Authors:  W C Laws; R A Bohannon; A J Robinson; P M Aggeler
Journal:  Calif Med       Date:  1968-09

Review 9.  Fibrin-based biomaterials: modulation of macroscopic properties through rational design at the molecular level.

Authors:  Ashley C Brown; Thomas H Barker
Journal:  Acta Biomater       Date:  2013-09-19       Impact factor: 8.947

10.  The significance of variations in immunoreactive and clottable fibrinogen in health and following thrombosis.

Authors:  P Wolf; G W Farrell; K W Walton
Journal:  J Clin Pathol       Date:  1972-01       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.